SCHEMBL2776545

SCHEMBL2776545

CCOC(=O)c1onc(-c2ccc(OC)cc2)c1C

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TARBP2 Q15633 2/20 0.54
PDCD4 Q53EL6 1/20 0.54
HTT P42858 2/20 0.52
POLB P06746 1/20 0.51
GAA P10253 1/20 0.51
MAPT P10636 3/20 0.51
NPC1 O15118 2/20 0.51
RAB9A P51151 2/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
PTGS2 P35354 3/20 0.49
PTGS1 P23219 1/20 0.49
PDE3A Q14432 1/20 0.49
GRM6 O15303 1/20 0.48
ALDH1A1 P00352 2/20 0.47
JAK2 O60674 1/20 0.47
JAK3 P52333 1/20 0.47
GABRA2 P47869 1/20 0.46
GABRB2 P47870 1/20 0.46
MAPK10 P53779 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2776072 0.86 KDM4E (0.52) GAAMAPTNPC1RAB9AL3MBTL1
SCHEMBL2775338 0.85 TARBP2 (0.50) TARBP2PDCD4HTTPOLBGAA
SCHEMBL2778520 0.85 ADORA3 (0.55) TARBP2POLBGAAMAPTNPC1
SCHEMBL2777783 0.83 CDC7 (0.47) ALDH1A1HPGDHSD17B10
SCHEMBL28805031 0.83 PTGS2 (0.53) MAPTPTGS2PTGS1PDE3AALDH1A1
SCHEMBL3661795 0.82 TARBP2 (0.39) TARBP2PDCD4HTTPOLBGAA
SCHEMBL15471965 0.82 TP53 (0.46) HTTPOLBGAAMAPTL3MBTL1
SCHEMBL5904542 0.82 MLYCD (0.50) MAPTL3MBTL1ALDH1A1GABRA2GABRB2
SCHEMBL2775071 0.81 GAA (0.64) TARBP2PDCD4HTTPOLBGAA
SCHEMBL2777468 0.77 PTGS2 (0.59) TARBP2PDCD4HTTPOLBGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2227475-B1 ISOXAZOLOPYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF HIF-MEDIATED CONDITIONS FIBROGEN INC (US) 2014-02-19 EP disclosed
US-8269008-B2 Oxazolopyridine and isoxazolopyridine derivatives for use in the treatment of HIF-mediated conditions FIBROGEN, INC. (US) 2012-09-18 US disclosed
US-20100303928-A1 ISOXAZOLOPYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF HIF-MEDIATED CONDITIONS FIBROGEN, INC. (US) 2010-12-02 US disclosed
EP-2227475-A1 ISOXAZOLOPYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF HIF-MEDIATED CONDITIONS Fibrogen, Inc. (US) 2010-09-15 EP disclosed
WO-2009073669-A1 ISOXAZOLOPYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF HIF-MEDIATED CONDITIONS FIBROGEN, INC. (US) 2009-06-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100303928-A1 ISOXAZOLOPYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF HIF-MEDIATED CONDITIONS HIF1AN, HIF1A, EGLN2 TARBP2 4814/4885PDCD4 1962/4885HTT 2287/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.